{"product_id":"vrtx-business-model-canvas","title":"Vertex Pharmaceuticals Incorporated (VRTX): Business Model Canvas [June-2026 Updated]","description":"\u003cp\u003eYou get a ready-made, research-based analysis of Vertex Pharmaceuticals Incorporated Business that shows how the company creates, delivers, and captures value through CF leadership, first-in-class gene editing, pain, and kidney disease programs. It highlights key numbers such as \u003cstrong\u003eover 1,500 active patents\u003c\/strong\u003e and \u003cstrong\u003e$13.0 billion\u003c\/strong\u003e in cash and securities, plus major partnerships, Authorized Treatment Centers, FDA and EMA regulation, and revenue drivers like TRIKAFTA\/KAFTRIO, ALYFTREK, CASGEVY, and JOURNAVX. You can use it to understand customer segments, channels, cost pressures, and strategic resources for coursework, case studies, essays, or business analysis projects.\u003c\/p\u003e\u003ch2\u003eVertex Pharmaceuticals Incorporated - Canvas Business Model: Key Partnerships\u003c\/h2\u003e\n\u003cp\u003eVertex Pharmaceuticals Incorporated relies on 5 partnership layers here: 1 research partner for cystic fibrosis mRNA work, specialized treatment centers for CASGEVY, government and private payers, non-profit access partners for low- and middle-income countries, and regulators. The main numeric anchors are \u003cstrong\u003e$2.2 million\u003c\/strong\u003e for CASGEVY's U.S. list price, \u003cstrong\u003e2\u003c\/strong\u003e U.S. indications, and an age threshold of \u003cstrong\u003e12\u003c\/strong\u003e years and older.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003ePartnership\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eReal-life numbers or amounts\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eBusiness model role\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eModerna CF mRNA collaboration\u003c\/td\u003e\n\u003ctd\u003e1 collaboration; 0 public dollar terms disclosed\u003c\/td\u003e\n\u003ctd\u003eResearch path for cystic fibrosis beyond CFTR modulators\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAuthorized Treatment Centers for CASGEVY\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e12\u003c\/strong\u003e+ years; \u003cstrong\u003e2\u003c\/strong\u003e U.S. indications; \u003cstrong\u003e1\u003c\/strong\u003e cell collection, \u003cstrong\u003e1\u003c\/strong\u003e conditioning regimen, \u003cstrong\u003e1\u003c\/strong\u003e infusion\u003c\/td\u003e\n\u003ctd\u003eControls delivery, safety, and capacity for a one-time cell therapy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGovernment and private payers\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$2.2 million\u003c\/strong\u003e U.S. list price; \u003cstrong\u003e1\u003c\/strong\u003e-time treatment economics\u003c\/td\u003e\n\u003ctd\u003eDetermines reimbursement and patient access\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon-profit access partners for LMIC CASGEVY access\u003c\/td\u003e\n\u003ctd\u003e0 public dollar amount or patient target disclosed\u003c\/td\u003e\n\u003ctd\u003eSupports access design and health-system entry in lower-income markets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEMA, FDA, and other regulators\u003c\/td\u003e\n\u003ctd\u003eFDA approval \u003cstrong\u003eDecember 8, 2023\u003c\/strong\u003e; EU authorization \u003cstrong\u003e2024\u003c\/strong\u003e; \u003cstrong\u003e2\u003c\/strong\u003e U.S. indications\u003c\/td\u003e\n\u003ctd\u003eSets approval, labeling, manufacturing, and follow-up rules\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eModerna CF mRNA collaboration.\u003c\/strong\u003e This is a 1-partnership science layer, and no public dollar terms were disclosed. The strategic value is that mRNA gives Vertex a second cystic fibrosis research path beyond small-molecule CFTR modulators, which matters because CFTR is the protein target behind the disease. The partnership helps Vertex keep working on patients whose mutations are not fully served by current medicines. In business-model terms, this is an upstream R\u0026amp;D partnership, not a near-term commercial channel.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthorized Treatment Centers for CASGEVY.\u003c\/strong\u003e CASGEVY depends on specialized centers because the therapy involves \u003cstrong\u003e1\u003c\/strong\u003e cell collection, \u003cstrong\u003e1\u003c\/strong\u003e conditioning regimen, and \u003cstrong\u003e1\u003c\/strong\u003e infusion of edited cells. The U.S. label covers patients aged \u003cstrong\u003e12\u003c\/strong\u003e years and older with \u003cstrong\u003e2\u003c\/strong\u003e diseases: sickle cell disease and transfusion-dependent beta thalassemia. That makes the center network a real operating asset, because Vertex needs transplant-style infrastructure, trained staff, and patient routing before revenue can happen. CASGEVY was also the first CRISPR-based medicine approved in the U.S.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eGovernment and private payers.\u003c\/strong\u003e The key commercial number is CASGEVY's \u003cstrong\u003e$2.2 million\u003c\/strong\u003e U.S. list price. That puts payers at the center of the business model, because they decide whether the one-time therapy is reimbursed through Medicaid, Medicare, commercial insurance, or national health systems. The payer conversation is about whether one treatment can replace years of chronic care, transfusions, hospital use, and complication management. For Vertex, this partnership affects conversion rates, time to treatment, and how fast revenue turns into cash.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eNon-profit access partners for LMIC CASGEVY access.\u003c\/strong\u003e Vertex's access work in low- and middle-income countries matters because the disease burden is concentrated outside the richest health systems, while CASGEVY needs specialized cell-therapy infrastructure. No public dollar amount or patient target was disclosed. The partnership value sits in patient identification, affordability design, treatment navigation, and health-system readiness. That makes the access network important for long-run reach even when near-term sales are limited.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eEMA, FDA, and other regulators.\u003c\/strong\u003e Regulatory partners set the pace and geography of the franchise. The FDA approved CASGEVY on \u003cstrong\u003eDecember 8, 2023\u003c\/strong\u003e, and the European Union authorized it in \u003cstrong\u003e2024\u003c\/strong\u003e. Vertex also depends on other national regulators, including the U.K. MHRA, because approval, manufacturing controls, and post-treatment follow-up are regulated market by market. This partnership matters because it determines where Vertex can sell, what the label says, and how fast the company can expand access.\u003c\/p\u003e\u003ch2\u003eVertex Pharmaceuticals Incorporated - Canvas Business Model: Key Activities\u003c\/h2\u003e\n\u003cp\u003eVertex Pharmaceuticals Incorporated's key activities are built around \u003cstrong\u003e5\u003c\/strong\u003e cystic fibrosis medicines, \u003cstrong\u003e1\u003c\/strong\u003e approved non-opioid acute pain medicine, \u003cstrong\u003e2\u003c\/strong\u003e renal disease programs, and \u003cstrong\u003e1\u003c\/strong\u003e gene-editing therapy with \u003cstrong\u003e2\u003c\/strong\u003e approved U.S. indications.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eActivity\u003c\/th\u003e\n\u003cth\u003eReal-life numbers and facts\u003c\/th\u003e\n\u003cth\u003eBusiness-model role\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCF R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e5\u003c\/strong\u003e CF medicines; Trikafta U.S. label expanded to ages \u003cstrong\u003e2\u003c\/strong\u003e to \u003cstrong\u003e5\u003c\/strong\u003e; CF mutation coverage is about \u003cstrong\u003e90%\u003c\/strong\u003e of people with CF in eligible markets\u003c\/td\u003e\n\u003ctd\u003eExtends the core franchise\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePain R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e approved non-opioid acute pain medicine in \u003cstrong\u003e2025\u003c\/strong\u003e; \u003cstrong\u003e2\u003c\/strong\u003e phase 3 acute pain studies\u003c\/td\u003e\n\u003ctd\u003eCreates a new commercial line\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRenal R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e renal focus areas: APOL1-mediated kidney disease and IgA nephropathy; APOL1 has \u003cstrong\u003e2\u003c\/strong\u003e risk variants, G1 and G2\u003c\/td\u003e\n\u003ctd\u003eBuilds the next pipeline wave\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHematology R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003eCASGEVY with \u003cstrong\u003e2\u003c\/strong\u003e U.S. indications: sickle cell disease and transfusion-dependent beta thalassemia\u003c\/td\u003e\n\u003ctd\u003eMoves Vertex into gene editing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercialization\u003c\/td\u003e\n\u003ctd\u003e2023 revenue of \u003cstrong\u003e$9.869 billion\u003c\/strong\u003e; \u003cstrong\u003e2\u003c\/strong\u003e CASGEVY indications and \u003cstrong\u003e5\u003c\/strong\u003e CF medicines to sell and support\u003c\/td\u003e\n\u003ctd\u003eFunds R\u0026amp;D and access work\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing\u003c\/td\u003e\n\u003ctd\u003eCASGEVY is an autologous ex vivo therapy with \u003cstrong\u003e1\u003c\/strong\u003e patient-specific collection, editing, release, and reinfusion workflow\u003c\/td\u003e\n\u003ctd\u003eTurns science into supply\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eCF R\u0026amp;D is still the center of the model. The company has \u003cstrong\u003e5\u003c\/strong\u003e CF medicines in market, and the Trikafta label moved to children ages \u003cstrong\u003e2\u003c\/strong\u003e to \u003cstrong\u003e5\u003c\/strong\u003e in the U.S. That matters because CF is a chronic disease, so every younger-age expansion can add years of therapy rather than a single treatment event. The franchise also reaches about \u003cstrong\u003e90%\u003c\/strong\u003e of people with CF in eligible markets, so label maintenance and mutation coverage matter as much as new molecule discovery.\u003c\/p\u003e\n\n\u003cp\u003eLate-stage clinical trials and BLA filings are concentrated in hematology and renal medicine. CASGEVY went through the FDA biologics pathway and ended up with \u003cstrong\u003e2\u003c\/strong\u003e U.S. indications. In pain, Vertex moved through \u003cstrong\u003e2\u003c\/strong\u003e phase 3 acute pain studies before securing \u003cstrong\u003e1\u003c\/strong\u003e approval in \u003cstrong\u003e2025\u003c\/strong\u003e. That combination shows how the company uses late-stage trial design, endpoint selection, and regulatory filing discipline to convert pipeline assets into commercial products.\u003c\/p\u003e\n\n\u003cp\u003eGlobal commercialization and market access are operationally heavy because the company sells both chronic daily therapy and one-time high-value therapy. Vertex reported \u003cstrong\u003e$9.869 billion\u003c\/strong\u003e in 2023 revenue, with CF still doing most of the work. Market access teams have to support \u003cstrong\u003e5\u003c\/strong\u003e CF medicines, payer reviews, mutation testing, and treatment-center onboarding for CASGEVY's \u003cstrong\u003e2\u003c\/strong\u003e approved indications. That mix forces the company to manage reimbursement, specialty distribution, and physician adoption at the same time.\u003c\/p\u003e\n\n\u003cp\u003eCell and gene manufacturing is more than factory work for Vertex because CASGEVY is patient-specific. Each treatment uses \u003cstrong\u003e1\u003c\/strong\u003e autologous cell collection, \u003cstrong\u003e1\u003c\/strong\u003e gene-editing step, \u003cstrong\u003e1\u003c\/strong\u003e release process, and \u003cstrong\u003e1\u003c\/strong\u003e reinfusion event. That makes manufacturing part of the treatment timeline. In practice, supply reliability and turnaround time affect whether a patient can get treated, so manufacturing capacity is tied directly to commercialization.\u003c\/p\u003e\n\n\u003cp\u003eLifecycle management and label expansion keep the CF franchise alive after initial approval. The clearest example is Trikafta's expansion to ages \u003cstrong\u003e2\u003c\/strong\u003e to \u003cstrong\u003e5\u003c\/strong\u003e in the U.S. Vertex also keeps extending disease coverage through new indications, new ages, and new payer-relevant evidence. For a business built on specialty medicines, each label change can add a new patient segment without building an entirely new sales force from scratch.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e5\u003c\/strong\u003e marketed CF medicines anchor the franchise.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e U.S. CASGEVY indications anchor the gene-editing platform.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e phase 3 acute pain studies supported the pain launch path.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e renal disease areas define the next pipeline wave.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$9.869 billion\u003c\/strong\u003e in 2023 revenue shows why commercialization and access execution matter.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eVertex Pharmaceuticals Incorporated - Canvas Business Model: Key Resources\u003c\/h2\u003e\n\u003cp\u003eVertex Pharmaceuticals Incorporated's key resources are \u003cstrong\u003e1,500+\u003c\/strong\u003e active patents, \u003cstrong\u003e$13.0 billion\u003c\/strong\u003e in cash and securities, a global R\u0026amp;D and commercial workforce, Boston Seaport cell and gene manufacturing, and approved and pipeline assets.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e1,500+\u003c\/strong\u003e active patents\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$13.0 billion\u003c\/strong\u003e cash and securities\u003c\/li\u003e\n\u003cli\u003eGlobal R\u0026amp;D and commercial workforce\u003c\/li\u003e\n\u003cli\u003eBoston Seaport cell and gene manufacturing\u003c\/li\u003e\n\u003cli\u003eApproved and pipeline assets\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003ePatents are the legal resource that protects exclusivity. For Vertex Pharmaceuticals Incorporated, \u003cstrong\u003e1,500+\u003c\/strong\u003e active patents support drug pricing, limit direct copy competition, and extend the value of long development cycles.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003e$13.0 billion\u003c\/strong\u003e in cash and securities is a major operating resource. It funds late-stage trials, regulatory submissions, manufacturing scale-up, and product launches without near-term financing pressure.\u003c\/p\u003e\n\n\u003cp\u003eThe global R\u0026amp;D and commercial workforce is the execution resource. It covers discovery science, clinical development, regulatory affairs, manufacturing operations, quality control, market access, and sales execution.\u003c\/p\u003e\n\n\u003cp\u003eBoston Seaport cell and gene manufacturing is a physical and technical resource. It supports controlled production, release testing, and supply chain oversight for cell and gene therapy programs.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eKey resource\u003c\/th\u003e\n\u003cth\u003eReal-life number or amount\u003c\/th\u003e\n\u003cth\u003eBusiness role\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive patents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1,500+\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eExclusivity protection\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and securities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$13.0 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFunding for R\u0026amp;D and launches\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproved cystic fibrosis medicines\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCore commercial franchise\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproved cell and gene therapy assets\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDiversification beyond cystic fibrosis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe approved portfolio includes \u003cstrong\u003e4\u003c\/strong\u003e cystic fibrosis medicines: Kalydeco, Orkambi, Symdeko, and Trikafta.\u003c\/p\u003e\n\n\u003cp\u003eThe cell and gene therapy portfolio includes \u003cstrong\u003e1\u003c\/strong\u003e approved asset: Casgevy.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eApproved asset\u003c\/th\u003e\n\u003cth\u003eApproval year\u003c\/th\u003e\n\u003cth\u003eResource category\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKalydeco\u003c\/td\u003e\n\u003ctd\u003e2012\u003c\/td\u003e\n\u003ctd\u003eCystic fibrosis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrkambi\u003c\/td\u003e\n\u003ctd\u003e2015\u003c\/td\u003e\n\u003ctd\u003eCystic fibrosis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSymdeko\u003c\/td\u003e\n\u003ctd\u003e2018\u003c\/td\u003e\n\u003ctd\u003eCystic fibrosis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrikafta\u003c\/td\u003e\n\u003ctd\u003e2019\u003c\/td\u003e\n\u003ctd\u003eCystic fibrosis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCasgevy\u003c\/td\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003ctd\u003eCell and gene therapy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCystic fibrosis\u003c\/li\u003e\n\u003cli\u003eCell and gene therapy\u003c\/li\u003e\n\u003cli\u003eAPOL1-mediated kidney disease\u003c\/li\u003e\n\u003cli\u003ePain\u003c\/li\u003e\n\u003cli\u003eType 1 diabetes\u003c\/li\u003e\n\u003cli\u003eAlpha-1 antitrypsin deficiency\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eVertex Pharmaceuticals Incorporated's pipeline assets matter because they extend the company beyond a single franchise. The mix of rare disease, genetic medicine, and specialty therapy programs supports long-duration revenue potential.\u003c\/p\u003e\u003ch2\u003eVertex Pharmaceuticals Incorporated - Canvas Business Model: Value Propositions\u003c\/h2\u003e\n\u003cp\u003eVertex Pharmaceuticals Incorporated's value proposition is built on disease-modifying medicines with age-based labels from \u003cstrong\u003e4 months\u003c\/strong\u003e to \u003cstrong\u003e12 years and older\u003c\/strong\u003e, plus a first-in-class gene-editing therapy priced at \u003cstrong\u003e$2.2 million\u003c\/strong\u003e in the U.S. Its portfolio is designed to sell premium therapies for severe, genetically defined diseases rather than broad-volume primary-care drugs.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDisease-modifying therapies for severe unmet needs\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eVertex Pharmaceuticals Incorporated focuses on treatments that change the course of disease in cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, and APOL1-related kidney disease. The commercial logic is clear: these are high-burden conditions with limited options, so a therapy that targets the underlying biology can support premium pricing and long treatment duration.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eKalydeco: approved for patients \u003cstrong\u003e4 months and older\u003c\/strong\u003e.\u003c\/li\u003e\n \u003cli\u003eOrkambi: approved for patients \u003cstrong\u003e1 year and older\u003c\/strong\u003e.\u003c\/li\u003e\n \u003cli\u003eSymdeko: approved for patients \u003cstrong\u003e6 years and older\u003c\/strong\u003e.\u003c\/li\u003e\n \u003cli\u003eTrikafta: approved for patients \u003cstrong\u003e2 years and older\u003c\/strong\u003e.\u003c\/li\u003e\n \u003cli\u003eCasgevy: approved for patients \u003cstrong\u003e12 years and older\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eTherapy\u003c\/td\u003e\n\u003ctd\u003eAge or pricing number\u003c\/td\u003e\n\u003ctd\u003eValue proposition signal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKalydeco\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4 months and older\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEarly pediatric treatment access\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrkambi\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1 year and older\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLifecycle expansion in younger children\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSymdeko\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e6 years and older\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMutation-specific CF coverage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrikafta\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2 years and older\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBroad CF franchise anchor\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCasgevy\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOne-time curative therapy pricing model\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eCF franchise leadership and deep lifecycle expansion\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eVertex Pharmaceuticals Incorporated has \u003cstrong\u003e4\u003c\/strong\u003e approved cystic fibrosis transmembrane conductance regulator, or CFTR, modulators in market: Kalydeco, Orkambi, Symdeko, and Trikafta. The franchise is built around repeated label expansion by age and genotype, which lets the company move from infant treatment to adult treatment inside the same disease area.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e4\u003c\/strong\u003e approved CFTR modulators support a multi-product franchise.\u003c\/li\u003e\n \u003cli\u003eAge coverage runs from \u003cstrong\u003e4 months\u003c\/strong\u003e to adults.\u003c\/li\u003e\n \u003cli\u003eMutation coverage includes patients with \u003cstrong\u003e1\u003c\/strong\u003e or \u003cstrong\u003e2\u003c\/strong\u003e copies of F508del, depending on the product.\u003c\/li\u003e\n \u003cli\u003eTrikafta is approved for patients with \u003cstrong\u003eat least 1\u003c\/strong\u003e F508del mutation or another responsive mutation.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThat structure matters because every new pediatric label can extend treatment duration across a patient's life. It also reduces dependence on one launch year, since the same franchise can keep expanding through smaller age bands and broader mutation coverage instead of relying only on new diseases.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFirst-in-class gene editing and pain options\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCasgevy is Vertex Pharmaceuticals Incorporated's first approved gene-editing therapy and its first medicine in sickle cell disease and transfusion-dependent beta thalassemia. The U.S. list price was set at \u003cstrong\u003e$2.2 million\u003c\/strong\u003e, which places it in the ultra-high-value specialty segment and shows how the company monetizes one-time treatment outcomes rather than chronic dosing alone.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCasgevy is approved for patients \u003cstrong\u003e12 years and older\u003c\/strong\u003e.\u003c\/li\u003e\n \u003cli\u003eCasgevy covers \u003cstrong\u003e2\u003c\/strong\u003e blood disorders: sickle cell disease and transfusion-dependent beta thalassemia.\u003c\/li\u003e\n \u003cli\u003eVertex Pharmaceuticals Incorporated also advanced a non-opioid pain program through \u003cstrong\u003e2\u003c\/strong\u003e Phase \u003cstrong\u003e3\u003c\/strong\u003e studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe pain program matters strategically because it reduces reliance on CF revenue. A successful non-opioid pain drug can bring a new specialty market with different prescribing patterns, different payor dynamics, and a separate growth curve from cystic fibrosis.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eEmerging renal therapy with rapid response data\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eVertex Pharmaceuticals Incorporated's renal work centers on APOL1-mediated kidney disease. The company reported early response data at \u003cstrong\u003e13 weeks\u003c\/strong\u003e, which is important because kidney medicines often need to show measurable proteinuria changes quickly to support later-stage development.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eRenal program metric\u003c\/td\u003e\n\u003ctd\u003eNumber\u003c\/td\u003e\n\u003ctd\u003eWhy it matters\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReadout time\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e13 weeks\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFast signal for kidney disease development\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevelopment stage\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003ePhase 2\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eStill early, but beyond first human testing\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReported response\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e47.6%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eShows a large proteinuria reduction signal\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eIn academic work, this renal program is useful as an example of how Vertex Pharmaceuticals Incorporated uses biomarker-driven development. Proteinuria, or excess protein in the urine, is a standard kidney-disease marker, so a \u003cstrong\u003e47.6%\u003c\/strong\u003e reduction at \u003cstrong\u003e13 weeks\u003c\/strong\u003e can be framed as early evidence of disease biology control rather than symptom relief.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eHigh-value specialty medicines with broad access support\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eVertex Pharmaceuticals Incorporated's business model depends on premium specialty pricing, payer access, and long-duration treatment in rare disease. The company reported \u003cstrong\u003e$9.87 billion\u003c\/strong\u003e in revenue in \u003cstrong\u003e2023\u003c\/strong\u003e, which shows how a concentrated rare-disease portfolio can produce large-scale commercial value from relatively small patient populations.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$9.87 billion\u003c\/strong\u003e in 2023 revenue.\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e4\u003c\/strong\u003e CFTR modulators across multiple pediatric and adult age bands.\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e$2.2 million\u003c\/strong\u003e U.S. list price for Casgevy.\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e12 years and older\u003c\/strong\u003e for Casgevy, versus \u003cstrong\u003e4 months\u003c\/strong\u003e, \u003cstrong\u003e1 year\u003c\/strong\u003e, \u003cstrong\u003e2 years\u003c\/strong\u003e, and \u003cstrong\u003e6 years\u003c\/strong\u003e for the CF franchise.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThis mix of age expansion, mutation-specific labeling, and premium pricing is the clearest expression of the company's value proposition. You can use it in case studies to show how Vertex Pharmaceuticals Incorporated captures value from severe, genetically defined diseases with a model built around precision medicine, long treatment duration, and specialty reimbursement.\u003c\/p\u003e\u003ch2\u003eVertex Pharmaceuticals Incorporated - Canvas Business Model: Customer Relationships\u003c\/h2\u003e\n\u003cp\u003eVertex Pharmaceuticals Incorporated's customer relationships are specialist-led, payer-heavy, and long-duration. The clearest numeric anchors are \u003cstrong\u003e$9.869 billion\u003c\/strong\u003e of 2023 revenue, a \u003cstrong\u003e$2.2 million\u003c\/strong\u003e U.S. list price for its one-time gene-editing therapy, and \u003cstrong\u003e15\u003c\/strong\u003e-year follow-up after gene-editing treatment.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePhysician education and field support\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eVertex Pharmaceuticals Incorporated depends on specialist physicians, not mass-market prescribing. The relationship model centers on training for genotype-based eligibility, treatment sequencing, and safety monitoring in cystic fibrosis and rare blood disorders. For the gene-editing therapy, U.S. approval covers patients aged \u003cstrong\u003e12\u003c\/strong\u003e years and older, which makes physician education tightly linked to patient selection and referral timing. Field support matters because treatment decisions are concentrated in specialty clinics and Authorized Treatment Centers, where one referral can determine whether a patient ever reaches therapy.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eRelationship channel\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eNumeric anchor\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eCustomer relationship effect\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialist prescribing\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e12\u003c\/strong\u003e-and-older U.S. approval\u003c\/td\u003e\n\u003ctd\u003eFocuses education on specialist physicians and referral pathways\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLong-term monitoring\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e15\u003c\/strong\u003e-year follow-up\u003c\/td\u003e\n\u003ctd\u003eExpands physician contact beyond the initial treatment event\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial scale\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$9.869 billion\u003c\/strong\u003e 2023 revenue\u003c\/td\u003e\n\u003ctd\u003eMakes physician access and retention commercially material\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003ePatient support programs\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePatient support is central because Vertex Pharmaceuticals Incorporated sells specialty therapies with high access friction. A \u003cstrong\u003e$2.2 million\u003c\/strong\u003e one-time therapy creates insurance, prior authorization, and affordability pressure that normal retail pharmacy programs do not face. Support therefore has to cover benefit checks, reimbursement navigation, and treatment logistics. The customer relationship is not just with the patient; it also includes caregivers, specialty nurses, and coordinating clinics. For long-term diseases such as cystic fibrosis, support extends across repeated contact points instead of a single dispensing event.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$2.2 million\u003c\/strong\u003e U.S. list price for the one-time gene-editing therapy\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e-time administration for the gene-editing therapy\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e15\u003c\/strong\u003e-year follow-up after gene-editing treatment\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eReimbursement and value-based contracting\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eReimbursement is one of the strongest relationship drivers because the economics are concentrated in a few high-value treatments. A therapy priced at \u003cstrong\u003e$2.2 million\u003c\/strong\u003e per patient cannot move through the market without payer approval, prior authorization, and often structured contracting. Value-based contracting matters because payers want evidence that the clinical benefit lasts long enough to justify the upfront cost. Vertex Pharmaceuticals Incorporated's \u003cstrong\u003e$9.869 billion\u003c\/strong\u003e 2023 revenue shows scale, but it also shows dependence on uninterrupted access in specialty channels. In academic work, this is a clear example of how pricing changes the customer relationship from simple purchase to multi-party negotiation.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eATC-based treatment coordination\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAuthorized Treatment Centers are the operational center of the customer relationship for the gene-editing therapy. The \u003cstrong\u003e12\u003c\/strong\u003e-and-older approval creates a narrow eligible population, while the \u003cstrong\u003e1\u003c\/strong\u003e-time treatment model requires cell collection, conditioning, infusion, and follow-up to be coordinated inside a controlled clinical setting. That makes the ATC the main interface among Vertex Pharmaceuticals Incorporated, physicians, payers, nurses, and patients. The relationship is therefore highly managed and highly specialized, not transactional.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eATC coordination step\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eReal-life number\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eWhy it matters\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEligibility\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e12\u003c\/strong\u003e years and older\u003c\/td\u003e\n\u003ctd\u003eNarrows the referral base to a defined patient group\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTreatment event\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e-time administration\u003c\/td\u003e\n\u003ctd\u003eMakes the treatment path center on one coordinated episode\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePost-treatment monitoring\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e15\u003c\/strong\u003e years\u003c\/td\u003e\n\u003ctd\u003eCreates a long service tail for clinical follow-up\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eLong-term specialty care management\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLong-term care management is essential because Vertex Pharmaceuticals Incorporated's customer relationship does not end at the point of prescribing. For chronic diseases, patients stay on therapy for years, which keeps clinicians, pharmacists, and payers in the relationship. For gene editing, the follow-up obligation lasts \u003cstrong\u003e15\u003c\/strong\u003e years, so post-treatment care becomes part of the commercial model. This long time horizon explains why access, adherence, safety monitoring, and reimbursement support are all part of the same customer relationship. The company's \u003cstrong\u003e$9.869 billion\u003c\/strong\u003e revenue base depends on that continuity.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e15\u003c\/strong\u003e-year follow-up after gene-editing treatment\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$9.869 billion\u003c\/strong\u003e 2023 revenue base\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$2.2 million\u003c\/strong\u003e U.S. list price for the one-time therapy\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e12\u003c\/strong\u003e-and-older approved patient population in the U.S.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eVertex Pharmaceuticals Incorporated - Canvas Business Model: Channels\u003c\/h2\u003e\n\u003cp\u003eVertex Pharmaceuticals Incorporated uses \u003cstrong\u003especialty physicians, treatment centers, hospitals, payers, and commercial field teams\u003c\/strong\u003e rather than a mass retail model. In \u003cstrong\u003e2025\u003c\/strong\u003e, JOURNAVX added a direct-to-consumer path to a channel system that already depended on specialist-led rare-disease access.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eNumeric fact\u003c\/th\u003e\n\u003cth\u003eChannel role\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty physicians and treatment centers\u003c\/td\u003e\n\u003ctd\u003eCasgevy: \u003cstrong\u003e12+\u003c\/strong\u003e; JOURNAVX: \u003cstrong\u003e18+\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eSpecialists initiate treatment for rare disease and acute pain.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect-to-consumer JOURNAVX marketing\u003c\/td\u003e\n\u003ctd\u003eU.S. approval: \u003cstrong\u003e2025-01-30\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003ePatient demand generation for an adult-only pain medicine.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospital and ATC networks\u003c\/td\u003e\n\u003ctd\u003eCasgevy: \u003cstrong\u003e1\u003c\/strong\u003e autologous treatment course per patient; \u003cstrong\u003e3\u003c\/strong\u003e treatment stages\u003c\/td\u003e\n\u003ctd\u003eHospitals and procedure sites handle collection, conditioning, and infusion.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal payer and reimbursement pathways\u003c\/td\u003e\n\u003ctd\u003eCasgevy price: \u003cstrong\u003e$2,200,000\u003c\/strong\u003e; approved indications: \u003cstrong\u003e2\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eCoverage and prior authorization determine access speed and volume.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial field sales teams\u003c\/td\u003e\n\u003ctd\u003e2025 launch products: \u003cstrong\u003e2\u003c\/strong\u003e (Casgevy and JOURNAVX)\u003c\/td\u003e\n\u003ctd\u003eField teams support specialists, hospitals, and payers.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eSpecialty physicians and treatment centers\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCasgevy is approved for patients \u003cstrong\u003e12\u003c\/strong\u003e years and older with sickle cell disease and transfusion-dependent beta-thalassemia.\u003c\/li\u003e\n\u003cli\u003eJOURNAVX is approved for adults \u003cstrong\u003e18\u003c\/strong\u003e years and older with moderate-to-severe acute pain.\u003c\/li\u003e\n\u003cli\u003eThis creates \u003cstrong\u003e2\u003c\/strong\u003e different specialist paths: chronic rare-disease care and acute pain prescribing.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eDirect-to-consumer JOURNAVX marketing\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eVertex Pharmaceuticals Incorporated opened a consumer-facing channel in \u003cstrong\u003e2025\u003c\/strong\u003e after JOURNAVX approval on \u003cstrong\u003e2025-01-30\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe target audience is adults \u003cstrong\u003e18+\u003c\/strong\u003e, which fits pharmacy and patient-education marketing better than pediatric products.\u003c\/li\u003e\n\u003cli\u003eThis channel matters because acute pain treatment can start with patient awareness before the prescription is written.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eHospital and ATC networks\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCasgevy is a \u003cstrong\u003e1\u003c\/strong\u003e-time autologous treatment course rather than a chronic refill product.\u003c\/li\u003e\n\u003cli\u003eThe workflow has \u003cstrong\u003e3\u003c\/strong\u003e stages: cell collection, conditioning, and infusion.\u003c\/li\u003e\n\u003cli\u003eHospital and ATC sites matter because these steps cannot move through a standard retail pharmacy channel.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eGlobal payer and reimbursement pathways\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCasgevy's \u003cstrong\u003e$2,200,000\u003c\/strong\u003e price makes reimbursement a central channel, not a back-office issue.\u003c\/li\u003e\n\u003cli\u003eCasgevy has \u003cstrong\u003e2\u003c\/strong\u003e approved indications, so access work has to cover both sickle cell disease and transfusion-dependent beta-thalassemia.\u003c\/li\u003e\n\u003cli\u003eThe channel split is usually \u003cstrong\u003e2\u003c\/strong\u003e benefit types in the U.S.: medical benefit for infused therapies and pharmacy benefit for oral drugs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCommercial field sales teams\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eVertex Pharmaceuticals Incorporated had to run \u003cstrong\u003e2\u003c\/strong\u003e launch motions in \u003cstrong\u003e2025\u003c\/strong\u003e: a specialty rare-disease motion for Casgevy and a consumer-plus-prescriber motion for JOURNAVX.\u003c\/li\u003e\n\u003cli\u003eThe sales mix has to cover \u003cstrong\u003e2\u003c\/strong\u003e care settings: specialty clinics and hospital or ATC sites.\u003c\/li\u003e\n\u003cli\u003eField coverage is tied to \u003cstrong\u003e12+\u003c\/strong\u003e rare-disease eligibility and \u003cstrong\u003e18+\u003c\/strong\u003e adult pain prescribing.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eVertex Pharmaceuticals Incorporated - Canvas Business Model: Customer Segments\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e$9.87B\u003c\/strong\u003e in 2023 product revenue points to a customer base built around rare-disease patients, specialty centers, and payers that can support high-cost specialty medicines.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eSegment\u003c\/td\u003e\n\u003ctd\u003eReal-life customer facts\u003c\/td\u003e\n\u003ctd\u003eBuying and care channel\u003c\/td\u003e\n\u003ctd\u003eCommercial pattern\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCF patients\u003c\/td\u003e\n\u003ctd\u003eAbout \u003cstrong\u003e40,000\u003c\/strong\u003e people in the U.S.; carrier rate \u003cstrong\u003e1 in 35\u003c\/strong\u003e; birth incidence \u003cstrong\u003e1 in 3,500\u003c\/strong\u003e; treatment label age \u003cstrong\u003e2+\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eCF centers, pediatric pulmonology, adult pulmonology, specialty pharmacies\u003c\/td\u003e\n\u003ctd\u003eChronic daily therapy and lifelong follow-up\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSCD and TDT patients\u003c\/td\u003e\n\u003ctd\u003eAbout \u003cstrong\u003e100,000\u003c\/strong\u003e people in the U.S. with sickle cell disease; Black birth incidence \u003cstrong\u003e1 in 365\u003c\/strong\u003e; Casgevy label age \u003cstrong\u003e12+\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eHematology, transplant centers, hospitals, payers\u003c\/td\u003e\n\u003ctd\u003eOne-time therapy, prior authorization, intensive clinical coordination\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcute pain patients\u003c\/td\u003e\n\u003ctd\u003eAdult patients with moderate-to-severe acute pain after surgery\u003c\/td\u003e\n\u003ctd\u003eSurgeons, anesthesiologists, hospitals, outpatient surgery centers\u003c\/td\u003e\n\u003ctd\u003eEpisodic perioperative use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIgA nephropathy and other kidney disease patients\u003c\/td\u003e\n\u003ctd\u003eIgA nephropathy is the most common primary glomerular disease worldwide; APOL1 high-risk genotype about \u003cstrong\u003e13%\u003c\/strong\u003e in Black Americans; Alpine acquisition \u003cstrong\u003e$4.9B\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eNephrology, academic medical centers, payers\u003c\/td\u003e\n\u003ctd\u003eChronic specialty immunology-nephrology use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialists, hospitals, and payers\u003c\/td\u003e\n\u003ctd\u003eCF centers, hematologists, nephrologists, surgeons, transplant teams, commercial payers, Medicare, Medicaid\u003c\/td\u003e\n\u003ctd\u003eSpecialty pharmacy, hospital outpatient, infusion, transplant, and prior-authorization channels\u003c\/td\u003e\n\u003ctd\u003eAccess, reimbursement, and procedure-based adoption\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eCF patients\u003c\/strong\u003e are the core base. The market is concentrated in long-term treatment, not one-off prescriptions. The \u003cstrong\u003e2+\u003c\/strong\u003e age label expands use into pediatrics, while the \u003cstrong\u003e40,000\u003c\/strong\u003e U.S. patient base supports recurring refills, dose updates, and long follow-up inside CF specialty centers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e40,000\u003c\/strong\u003e U.S. patients\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e1 in 35\u003c\/strong\u003e carrier rate in the U.S.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e1 in 3,500\u003c\/strong\u003e U.S. births\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2+\u003c\/strong\u003e treatment age\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eSCD and TDT patients\u003c\/strong\u003e are a separate rare-disease segment with a very different buying pattern. The \u003cstrong\u003e100,000\u003c\/strong\u003e U.S. sickle cell population and the \u003cstrong\u003e1 in 365\u003c\/strong\u003e Black birth incidence make access, transplant capacity, and payer approval central. Casgevy's \u003cstrong\u003e12+\u003c\/strong\u003e label keeps the first wave in adolescent and adult patients, while transfusion-dependent beta-thalassemia requires repeated blood transfusion history before treatment selection.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e100,000\u003c\/strong\u003e U.S. sickle cell patients\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e1 in 365\u003c\/strong\u003e Black births affected in the U.S.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e12+\u003c\/strong\u003e label age for Casgevy\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e treatment course replaces chronic transfusion dependence for selected patients\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eAcute pain patients\u003c\/strong\u003e are an episodic, procedure-linked customer segment. The demand sits in adult surgical settings, where surgeons, anesthesiologists, hospitals, and outpatient surgery centers control prescribing. This segment is commercially different from CF and SCD because it depends on short-duration use, formularies, and perioperative protocols rather than lifelong therapy.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eAdult\u003c\/strong\u003e patients\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e post-surgical episode can drive use\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e major care settings matter most: hospital and outpatient surgery center\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eIgA nephropathy and other kidney disease patients\u003c\/strong\u003e are a chronic specialty segment tied to nephrology and immunology. IgA nephropathy is the most common primary glomerular disease worldwide, and APOL1 high-risk genotype prevalence of about \u003cstrong\u003e13%\u003c\/strong\u003e in Black Americans shows why Vertex has also looked at genetically defined kidney disease. The \u003cstrong\u003e$4.9B\u003c\/strong\u003e Alpine acquisition shows that this segment is large enough for major capital deployment even before broad commercial scale.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIgA nephropathy: most common primary glomerular disease worldwide\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e13%\u003c\/strong\u003e APOL1 high-risk genotype prevalence in Black Americans\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$4.9B\u003c\/strong\u003e Alpine acquisition price\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e chronic nephrology specialty path, not a primary-care path\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eSpecialists, hospitals, and payers\u003c\/strong\u003e are the gatekeepers across every segment. CF centers, hematology transplant programs, nephrologists, and surgical teams decide eligibility, timing, and monitoring. Payers such as commercial plans, Medicare, and Medicaid control access through prior authorization, site-of-care rules, and reimbursement. For high-cost therapies, the customer is rarely one person; it is the patient, the specialist, the hospital, and the payer acting together.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e3\u003c\/strong\u003e payer groups that matter most: commercial, Medicare, Medicaid\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e4\u003c\/strong\u003e core specialist groups: pulmonology, hematology, nephrology, surgery\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e approval pathway can depend on specialty-center documentation and payer review\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eVertex Pharmaceuticals Incorporated - Canvas Business Model: Cost Structure\u003c\/h2\u003e\n\u003cp\u003eVertex Pharmaceuticals Incorporated reported \u003cstrong\u003e$9.869 billion\u003c\/strong\u003e of revenue in 2023, with \u003cstrong\u003e$3.394 billion\u003c\/strong\u003e of research and development expense and \u003cstrong\u003e$1.748 billion\u003c\/strong\u003e of selling, general and administrative expense. Those two cost lines totaled \u003cstrong\u003e$5.142 billion\u003c\/strong\u003e, or \u003cstrong\u003e52.1%\u003c\/strong\u003e of revenue.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003e2023 cost line\u003c\/th\u003e\n\u003cth\u003eAmount\u003c\/th\u003e\n\u003cth\u003eShare of revenue\u003c\/th\u003e\n\u003cth\u003eMonthly average\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$9.869 billion\u003c\/td\u003e\n\u003ctd\u003e100.0%\u003c\/td\u003e\n\u003ctd\u003e$822.4 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch and development\u003c\/td\u003e\n\u003ctd\u003e$3.394 billion\u003c\/td\u003e\n\u003ctd\u003e34.4%\u003c\/td\u003e\n\u003ctd\u003e$282.8 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSelling, general and administrative\u003c\/td\u003e\n\u003ctd\u003e$1.748 billion\u003c\/td\u003e\n\u003ctd\u003e17.7%\u003c\/td\u003e\n\u003ctd\u003e$145.7 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D and SG\u0026amp;A combined\u003c\/td\u003e\n\u003ctd\u003e$5.142 billion\u003c\/td\u003e\n\u003ctd\u003e52.1%\u003c\/td\u003e\n\u003ctd\u003e$428.5 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eHeavy R\u0026amp;D and clinical trial spend\u003c\/strong\u003e: \u003cstrong\u003e$3.394 billion\u003c\/strong\u003e, or \u003cstrong\u003e34.4%\u003c\/strong\u003e of revenue.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eSG\u0026amp;A and launch commercialization costs\u003c\/strong\u003e: \u003cstrong\u003e$1.748 billion\u003c\/strong\u003e, or \u003cstrong\u003e17.7%\u003c\/strong\u003e of revenue.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eManufacturing and supply chain investments\u003c\/strong\u003e: \u003cstrong\u003e$5.142 billion\u003c\/strong\u003e in combined R\u0026amp;D and SG\u0026amp;A expense.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCell therapy logistics and ATC support\u003c\/strong\u003e: \u003cstrong\u003e$1.748 billion\u003c\/strong\u003e in SG\u0026amp;A expense.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eShare-based compensation and integration costs\u003c\/strong\u003e: \u003cstrong\u003e$5.142 billion\u003c\/strong\u003e in combined R\u0026amp;D and SG\u0026amp;A expense.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$3.394 billion\u003c\/strong\u003e research and development expense\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$1.748 billion\u003c\/strong\u003e selling, general and administrative expense\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$5.142 billion\u003c\/strong\u003e combined R\u0026amp;D and SG\u0026amp;A expense\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e34.4%\u003c\/strong\u003e R\u0026amp;D as a share of revenue\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e17.7%\u003c\/strong\u003e SG\u0026amp;A as a share of revenue\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e52.1%\u003c\/strong\u003e combined R\u0026amp;D and SG\u0026amp;A as a share of revenue\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$282.8 million\u003c\/strong\u003e average monthly R\u0026amp;D expense\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$145.7 million\u003c\/strong\u003e average monthly SG\u0026amp;A expense\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$428.5 million\u003c\/strong\u003e average monthly combined R\u0026amp;D and SG\u0026amp;A expense\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eVertex Pharmaceuticals Incorporated - Canvas Business Model: Revenue Streams\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e$11.02 billion\u003c\/strong\u003e in 2024 product revenue versus \u003cstrong\u003e$9.87 billion\u003c\/strong\u003e in 2023 equals \u003cstrong\u003e$1.15 billion\u003c\/strong\u003e growth.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e4\u003c\/strong\u003e commercial revenue streams and \u003cstrong\u003e1\u003c\/strong\u003e precommercial renal stream shape the mix.\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue stream\u003c\/td\u003e\n\u003ctd\u003eReal-life numeric anchor\u003c\/td\u003e\n\u003ctd\u003eRevenue profile\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTRIKAFTA\/KAFTRIO product sales\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$9.87 billion\u003c\/strong\u003e in 2023; \u003cstrong\u003e$11.02 billion\u003c\/strong\u003e in 2024; \u003cstrong\u003e2\u003c\/strong\u003e years and older\u003c\/td\u003e\n\u003ctd\u003eRecurring CF sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eALYFTREK product sales\u003c\/td\u003e\n\u003ctd\u003eFDA approval \u003cstrong\u003eDecember 20, 2024\u003c\/strong\u003e; \u003cstrong\u003e6\u003c\/strong\u003e years and older\u003c\/td\u003e\n\u003ctd\u003eNew CF launch\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCASGEVY revenue\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$2.2 million\u003c\/strong\u003e per treatment; \u003cstrong\u003e12\u003c\/strong\u003e years and older\u003c\/td\u003e\n\u003ctd\u003eOne-time gene-editing therapy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJOURNAVX revenue\u003c\/td\u003e\n\u003ctd\u003eFDA approval \u003cstrong\u003eJanuary 30, 2025\u003c\/strong\u003e; adults\u003c\/td\u003e\n\u003ctd\u003eAcute pain launch\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFuture renal and pipeline launches\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e0\u003c\/strong\u003e current commercial revenue\u003c\/td\u003e\n\u003ctd\u003ePrecommercial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$2.2 million\u003c\/strong\u003e CASGEVY treatment price\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e6\u003c\/strong\u003e years and older ALYFTREK label\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e years and older TRIKAFTA\/KAFTRIO label\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e12\u003c\/strong\u003e years and older CASGEVY label\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eJanuary 30, 2025\u003c\/strong\u003e JOURNAVX approval date\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":44601627836565,"sku":"vrtx-business-model-canvas","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/vrtx-business-model-canvas.png?v=1740228915","url":"https:\/\/dcf-model.com\/es\/products\/vrtx-business-model-canvas","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}